HitGen, Inc. Hits Day Low at CNY 29.35 Amid Price Pressure

HitGen, Inc., a prominent player in the Pharmaceuticals & Biotechnology sector, experienced a notable decline of 5.81% on May 28, 2026, reaching an intraday low of CNY 29.35. This performance comes amid a mixed market backdrop, as the China Shanghai Composite index recorded a slight increase of 0.12% on the same day. Despite the day's downturn, HitGen has shown resilience over the longer term, boasting a remarkable 96.9% increase over the past year, significantly outperforming the China Shanghai Composite's 22.72% gain. The company has also demonstrated strong financial metrics, including a net profit growth of 114.98% reported on September 25, and an operating cash flow of CNY 204.8 million, marking its highest level. With a market capitalization of CNY 11,980 million, HitGen maintains a price-to-earnings ratio of 74.00 and a return on equity of 9.11%. The stock's performance over the past three years has been particularly strong, with an increase of 87.72%, further solidifying its position as a reliable performer in the market.